GuideAI Health Partners With Boone Heart Institute on Clinical Study
The AI imaging software developer will evaluate its Elevate platform in preventive cardiology through a clinical study and pilot agreement.
GuideAI Health has entered a clinical study and software pilot agreement with Boone Heart Institute to evaluate artificial intelligence-assisted lower extremity CT angiography and test GuideAI's Elevate platform in a preventive cardiology setting.
The collaboration represents a strategic expansion for GuideAI Health into the preventive cardiology category, a growing segment where early detection of vascular disease drives clinical adoption. By embedding its AI-assisted imaging technology within Boone Heart Institute's existing workflows, GuideAI gains real-world validation data in a specialized clinical environment while Boone Heart Institute gains access to advanced diagnostic capabilities.
The Elevate platform, GuideAI's core software offering, is designed to augment radiologist workflows through AI-assisted image analysis. The agreement positions the platform for potential clinical integration in preventive cardiology practices, where lower extremity vascular imaging is a critical diagnostic tool. This pilot phase will generate performance data and clinical feedback essential for regulatory submissions and market expansion.
For GuideAI Health, the partnership signals movement beyond initial commercialization into evidence-generation phase. Clinical validation at an established cardiac institute strengthens the company's market positioning and provides case studies for downstream licensing conversations with health systems and imaging centers. The preventive cardiology category offers recurring revenue potential through software licensing and usage-based models.
Boone Heart Institute's participation in the clinical study and pilot indicates confidence in the technology's diagnostic accuracy and workflow integration. The institute gains early access to emerging AI capabilities while contributing to clinical evidence that may inform broader adoption across the preventive cardiology sector.
The duration of the clinical study and specific financial terms were not disclosed. Success in this pilot phase could establish GuideAI Health as a preferred technology partner for preventive cardiology imaging, opening pathways to multi-site deployments and category expansion beyond lower extremity angiography.